LON:REDX

Redx Pharma (REDX) Share Price, News & Analysis

Redx Pharma logo

About Redx Pharma Stock (LON:REDX)

Key Stats

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
1.42 million shs
Average Volume
707,637 shs
Market Capitalization
£58.35 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Redx Pharma Plc engages in drug discovery, pre-clinical development, and licensing activities in the United Kingdom. It discovers and develops small molecule drugs for treating fibrotic disease, cancer, and the emerging area of cancer-associated fibrosis in the areas of unmet medical needs. The company also develops zelasudil (RXC007), a selective rho associated coiled-coil containing protein kinase 2 (ROCK2) inhibitor, which is in Phase 2 clinical trial for the treatment of multiple interstitial lung diseases and cancer-associated fibrosis; RXC008, a potential first-in-class GI-targeted ROCK inhibitor that is in preclinical studies for the treatment of fibrostenotic Crohn's disease; and zamaporvint (RXC004), a porcupine inhibitor that is in Phase 2 clinical trial for targeted therapy of Wnt-ligand dependent cancers. In addition, it is developing RXC009, a potent and selective DDR1 inhibitor, which is in preclinical studies for the treatment of chronic kidney disease; Kirsten rat sarcoma virus (KRAS) inhibitor to target G12D selective and multi-KRAS profiles; RXC006/AZD5055 a porcupine inhibitor, which is in Phase 1 clinical trial for targeting fibrotic diseases, including idiopathic pulmonary fibrosis; JZP815, a pan-rapidly accelerated fibrosarcoma inhibitor that is in Phase 1 clinical trial to overcome resistance mechanisms associated with clinically approved B-RAF selective drugs; and mitogen-activated protein kinase pathway targets for oncology indications. The company has research collaboration agreements with Jazz Pharmaceuticals plc to develop JZP815, as well as discovery and preclinical development of a targeted cancer therapy on the Ras/RAF/MAP kinase pathway; and AstraZeneca plc to develop RXC006/AZD5055, a Porcupine inhibitor for the treatment of fibrotic disease. Redx Pharma Plc was incorporated in 2010 and is based in Macclesfield, the United Kingdom.

Receive REDX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Redx Pharma and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

REDX Stock News Headlines

Every Starlink dish pays this stock
There's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now he's filed to launch 1,000,000 AI satellites, a move Dylan believes could mean a 100X bigger royalty bill starting December 8th. This free pick names the public company collecting on every unit.tc pixel
Big Pharma lacks motive to prep for new pandemics
Redx Pharma Says Not Involved in U.S.-Listing Process
See More Headlines

REDX Stock Analysis - Frequently Asked Questions

Redx Pharma Plc (LON:REDX) announced its quarterly earnings data on Monday, November, 19th. The company reported GBX (7) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of GBX (6.50) by GBX 0.50.

Based on aggregate information from My MarketBeat watchlists, some other companies that Redx Pharma investors own include Jubilee Metals Group (JLP), Automatic Data Processing (ADP), Academy Sports and Outdoors (ASO), Bank of New York Mellon (BNY), Atico Mining (ATY), BAE Systems (BA) and Barclays (BARC).

Industry, Sector and Symbol

Stock Exchange
LON
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
LON:REDX
CIK
N/A
Fax
N/A
Employees
101
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
GBX (0.10)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-£33.16 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-180.80%
Return on Assets
-43.95%

Debt

Debt-to-Equity Ratio
527.00
Current Ratio
1.11
Quick Ratio
1.93

Sales & Book Value

Annual Sales
£4.20 million
Price / Sales
0.00
Cash Flow
N/A
Price / Cash Flow
5.23
Book Value
GBX 1 per share
Price / Book
N/A

Miscellaneous

Outstanding Shares
388,990,000
Free Float
N/A
Market Cap
£58.35 million
Optionable
Not Optionable
Beta
-0.53
7 Stocks That Could Be Bigger Than Tesla, NVIDIA, and Google Cover

Could the next Tesla, NVIDIA, and Google be hiding in plain sight? Discover seven growth stocks with the potential to become tomorrow's market giants, fueled by breakthroughs in AI, nuclear energy, cybersecurity, and more.

Get This Free Report

This page (LON:REDX) was last updated on 4/30/2024 by MarketBeat.com Staff.
From Our Partners